Article info

Download PDFPDF
A phase II trial of intravenous etoposide (VP-16-213) in epithelial ovarian cancer resistant to cisplatin or carboplatin: clinical and serological evidence of activity

Authors

  • P. J. HOSKINS The Vancouver Clinic of the British Columbia Cancer Agency, (formerly A. Maxwell Evans Clinic of the Cancer Control Agency of British Columbia), Vancouver, Canada V5Z 4E6 PubMed articlesGoogle scholar articles
  • E. McMURTRIE The Vancouver Clinic of the British Columbia Cancer Agency, (formerly A. Maxwell Evans Clinic of the Cancer Control Agency of British Columbia), Vancouver, Canada V5Z 4E6 PubMed articlesGoogle scholar articles
  • K. D. SWENERTON The Vancouver Clinic of the British Columbia Cancer Agency, (formerly A. Maxwell Evans Clinic of the Cancer Control Agency of British Columbia), Vancouver, Canada V5Z 4E6 PubMed articlesGoogle scholar articles
  1. Address for correspondence: Dr P.J. Hoskins, British Columbia Cancer Agency, Vancouver Clinic, 600 W. Tenth Avenue, Vancouver, B.C., Canada V5Z 4E6.

Citation

HOSKINS PJ, McMURTRIE E, SWENERTON KD
A phase II trial of intravenous etoposide (VP-16-213) in epithelial ovarian cancer resistant to cisplatin or carboplatin: clinical and serological evidence of activity

Publication history

  • First published January 1, 1992.
Online issue publication 
January 01, 1992

Request permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.